188 related articles for article (PubMed ID: 14713268)
1. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Brockdorff BL; Heiberg I; Lykkesfeldt AE
Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
[TBL] [Abstract][Full Text] [Related]
7. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
8. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
[TBL] [Abstract][Full Text] [Related]
9. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
[TBL] [Abstract][Full Text] [Related]
11. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
13. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Lykkesfeldt AE; Larsen SS; Briand P
Int J Cancer; 1995 May; 61(4):529-34. PubMed ID: 7759159
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar K; Löffek S; Schulz T; Michna H; Diel P
Breast Cancer Res Treat; 2000 Oct; 63(3):249-59. PubMed ID: 11110059
[TBL] [Abstract][Full Text] [Related]
15. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
16. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
Sommer A; Hoffmann J; Lichtner RB; Schneider MR; Parczyk K
J Steroid Biochem Mol Biol; 2003 May; 85(1):33-47. PubMed ID: 12798355
[TBL] [Abstract][Full Text] [Related]
17. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
[TBL] [Abstract][Full Text] [Related]
19. A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Freddie CT; Christensen GL; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 May; 220(1-2):97-107. PubMed ID: 15196704
[TBL] [Abstract][Full Text] [Related]
20. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.
Diel P; Smolnikar K; Michna H
Breast Cancer Res Treat; 1999 Nov; 58(2):87-97. PubMed ID: 10674872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]